Lyell Immunopharma (NASDAQ:LYEL) Trading 4.9% Higher

Lyell Immunopharma, Inc. (NASDAQ:LYELGet Rating) traded up 4.9% on Monday . The stock traded as high as $7.99 and last traded at $7.96. 3,249 shares changed hands during trading, a decline of 100% from the average session volume of 1,002,793 shares. The stock had previously closed at $7.59.

Analyst Ratings Changes

Separately, The Goldman Sachs Group cut their price target on Lyell Immunopharma from $21.00 to $12.00 and set a “buy” rating on the stock in a research note on Tuesday, May 24th.

Lyell Immunopharma Trading Down 6.5 %

The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of -9.54 and a beta of -2.14. The firm’s 50-day moving average is $6.67 and its 200 day moving average is $5.83.

Lyell Immunopharma (NASDAQ:LYELGet Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.16. The company had revenue of $35.74 million for the quarter, compared to analyst estimates of $3.37 million. Lyell Immunopharma had a negative net margin of 566.14% and a negative return on equity of 25.87%. Analysts predict that Lyell Immunopharma, Inc. will post -1.15 EPS for the current year.

Hedge Funds Weigh In On Lyell Immunopharma

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC acquired a new position in shares of Lyell Immunopharma in the second quarter worth approximately $38,000. Royal Bank of Canada lifted its position in shares of Lyell Immunopharma by 76.1% in the 1st quarter. Royal Bank of Canada now owns 9,114 shares of the company’s stock worth $46,000 after purchasing an additional 3,940 shares during the period. Metropolitan Life Insurance Co NY acquired a new position in shares of Lyell Immunopharma in the 1st quarter worth approximately $50,000. Dynamic Technology Lab Private Ltd acquired a new position in Lyell Immunopharma in the first quarter valued at $52,000. Finally, Prudential Financial Inc. acquired a new position in Lyell Immunopharma in the first quarter valued at $55,000. 40.25% of the stock is owned by institutional investors and hedge funds.

Lyell Immunopharma Company Profile

(Get Rating)

Lyell Immunopharma, Inc, a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness.

Featured Stories

Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with's FREE daily email newsletter.